CytRx Corporation (CYTR) has an average broker rating of 1.67, which is interpreted as a Buy, as rated by 3 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 1, which is also a Strong Buy.
CytRx Corporation (CYTR) : The most positive equity analysts on CytRx Corporation (CYTR) expects the shares to touch $10, whereas, the least positive believes that the stock will trade at $3 in the short term. The company is covered by 3 Wall Street Brokerage Firms. The average price target for shares are $6.83 with an expected fluctuation of $3.88 from the mean.
CytRx Corporation (NASDAQ:CYTR): The stock was completely flat for the day, closing at $2.28 on Wednesday. The flat closing masks the intraday volatility in the stock. After opening at $2.28, the stock touched an intraday high of $2.35 and a low of $2.21. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $2.28. The total trading volume on Wednesday was 783,295.
The company shares have dropped -38.04% from its 1 Year high price. On Jul 16, 2015, the shares registered one year high at $4.20 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $2.48 and the 200 Day Moving Average price is recorded at $2.54.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.